Related Experiment Video
Updated: Jul 13, 2026
04:50
Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
Pharmacological interventions for psoriatic arthritis: present and future
1Dermatology, Gandhi Hospital & Gandhi Medical College, Hyderabad, India. kkr8621@yahoo.com
Indian Journal of Dermatology, Venereology and Leprology
|July 28, 2007
Summary
Psoriatic arthritis, a chronic inflammatory condition, shares treatments with rheumatoid arthritis. Newer therapies targeting pro-inflammatory cytokines like tumor necrosis factor alpha show promise for managing joint destruction in psoriatic arthritis.
Area of Science:
- Rheumatology
- Immunology
- Dermatology
Background:
- Psoriatic arthritis affects 5-7% of psoriasis patients.
- It is a chronic inflammatory condition.
- Current treatments often mirror those for rheumatoid arthritis.
Purpose of the Study:
- Review newer therapeutic developments for psoriatic arthritis.
- Re-evaluate existing treatment methods.
- Focus on agents inhibiting pro-inflammatory cytokines.
Main Methods:
- Literature review of current and emerging psoriatic arthritis therapies.
- Analysis of the role of pro-inflammatory cytokines, specifically tumor necrosis factor alpha.
- Evaluation of treatment strategies for joint destruction.
Main Results:
- Emerging agents targeting pro-inflammatory cytokines are a key focus.
- Tumor necrosis factor alpha inhibitors are significant in managing joint destruction.
- Established therapies remain relevant but are being augmented by novel approaches.
Conclusions:
- Newer biologic agents targeting cytokines offer improved psoriatic arthritis management.
- Comprehensive therapeutic strategies are essential for this disabling disorder.
- Continued research into cytokine inhibition is crucial for advancing treatment.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:28Drug Therapy
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Psychosis: Goals of Pharmacotherapy
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation. For...